Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma
Zanidatamab, in combination with tislelizumab and CAPOX, demonstrated clinically meaningful antitumor activity with a manageable safety profile as first-line therapy for patients with HER2+ gastric cancer/GEJC. These results support a further development of zanidatamab and tislelizumab with chemotherapy in this patient population in the ongoing phase III HERIZON-GEA-01 trial (NCT05152147).
Authors
- Li‐Yuan Bai (ORCID: https://orcid.org/0000-0001-7739-4077)
- Yoon‐Koo Kang (ORCID: https://orcid.org/0000-0003-0783-6583)
- Vincent Li (ORCID: https://orcid.org/0000-0003-1923-5232)
- Minkyu Jung (ORCID: https://orcid.org/0000-0001-8281-3387)
- Yee Chao (ORCID: https://orcid.org/0000-0001-5578-340X)
- Shengnan Chen (ORCID: https://orcid.org/0009-0000-8527-1464)
- Jieer Ying (ORCID: https://orcid.org/0000-0001-9452-1242)
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Sang Cheul Oh (ORCID: https://orcid.org/0000-0002-0527-6001)
- Keun‐Wook Lee (ORCID: https://orcid.org/0000-0002-8491-703X)
- Young‐Hyuck Im (ORCID: https://orcid.org/0000-0001-6459-8118)
- Ye Chen (ORCID: https://orcid.org/0009-0007-0115-2566)
- Jin Won Kim (ORCID: https://orcid.org/0000-0002-1357-7015)
- Jungwon Cho (ORCID: https://orcid.org/0009-0006-2362-706X)
Institutions
- Seoul National University (KR)
- China Medical University (TW)
- Yonsei University (KR)
- Severance Hospital (KR)
- Korea University Medical Center (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Taipei Veterans General Hospital (TW)
- Seoul National University Bundang Hospital (KR)
- University of Ulsan (KR)
- Zhejiang Cancer Hospital (CN)
- Beijing Enterprises (China) (CN)
- China Medical University Hospital (TW)
- Danone (China) (CN)
- Gangnam Severance Hospital (KR)
- Yonsei University Health System (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4295
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Array BioPharma
- Handok
- Merck KGaA
- Exelixis
- Astellas Pharma
- Servier
- Daiichi Sankyo Europe